Genotype-phenotype correlations in cystic fibrosis

Pediatric Pulmonology

Volumn 22, Issue 6, 1996, Pages 387-395

  Kerem, Eitan ^a   Kerem, Batsheva ^b  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORIDE; ISOPRENALINE; TERBUTALINE;

BRONCHUS MUCOSA; CYSTIC FIBROSIS; DIAGNOSTIC TEST; DISEASE ASSOCIATION; GENE MUTATION; GENETIC DISORDER; GENOTYPE; HUMAN; MALE GENITAL TRACT MALFORMATION; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SWEAT TEST; VAS DEFERENS;

CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FEMALE; GENE EXPRESSION; GENOTYPE; HUMANS; INFERTILITY, MALE; MALE; MUTATION; PHENOTYPE;

EID: 0030473619     PISSN: 87556863     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-0496(199612)22:6<387::AID-PPUL7>3.0.CO;2-G     Document Type: Review

References (76)

1. Welsh MJ, Tsui L.-C, Boat TF, Beaudet AL. Cystic fibrosis. In: Scriver CL, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease. 7th ed. New York: McGraw-Hill, 1995:3799-3876.
2. Highsmith WE, Lauraneli H, Burch MS, Zhou Z, Olsen JC, Boat TE, Spock A, Gorvoy JD, Quittell L, Friedman KJ, Silverman LM, Boucher RC, Knowles MR. A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations. N Engl J Med. 1994; 331:974-980.
3. Augarten A, Kerem B, Yahav Y, Noiman S, Rivlin Y, Tal Asher, Blau H, Ben-Tur L, Szeinberg A, Kerem E, Gazit E. Mild cystic fibrosis and normal or borderline sweat test in patients with the 3849 + 10 kb C→Tmutation. Lancet. 1993; 342:25-26.
4. Stewart B, Zabner J, Shuber AP, Welsh MJ, McCray PB, Normal sweat chloride values do not exclude the diagnosis of cystic fibrosis. Am J Respir Crit Care Med. 1995; 151:899-903.
5. Gaskin KJ, Gurwitz D, Dune P, Corey M, Levison H, Forstner G. Improved respiratory prognosis in patients with cystic fibrosis with normal fat absorption. J Pediatr. 1982; 100:857-862.
6. Corey M, Gaskin K, Durie P, Levison H, Forstner GG. Improved prognosis in CF patients with normal fat absorption. J Pediatr Gastroenterol Nutr. 1984; 3(Suppl 1):S99-S105.
7. Corey M, Durie P, Moore D, Forstner GG, Levison H. Familial concordance of pancreatic function in cystic fibrosis. J Pediatr. 1989; 115:274-277.
8. Cystic Fibrosis Genetic Analysis Consortium. Population variations of common cystic fibrosis mutations. Hum Mutat. 1994; 4:167-177.
9. Kerem B, Buchanan JA, Durie P, Corey M, Levison H. Buchwald M. Tsui L-C. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. Am J Hum Genet. 1989; 44:827-834.
10. Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, Chakravarti A, Buchwald M, Tsui L-C. Identification of the cystic fibrosis gene: Genetic analysis. Science. 1989; 245:1073-1080.
11. Rommens JM, Iannuzzi MC, Kerem B, Drumm ML, Melmer G, Dean M, Rozmahel R, Cole JL, Kennedy D, Hidaka N, Zsiga M, Buchwald M, Riordan JR, Tsui L.-C., Collins FS. Identification of the cystic fibrosis gene: Chromosome walking and jumping. Science. 1989; 245:1059-1065.
12. Riordan JR, Rommens JM. Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou J-L, Drumm ML, Iannuuzzi C. Collins FS, Tsui L-C. Identification of the cystic fibrosis gene. Cloning and characterization of complementary DNA. Science. 1989; 245:1066-1073.
13. Kerem E, Corey M, Kerem B, Rommens JM, Markiewicz D, Levison H, Tsui LC, Durie P. The relationship between genotype and phenotype in cystic fibrosis - analysis of the most common mutation (ΔF508). N Engl J Med. 1990; 323:1517-1522.
14. Santis G, Osborne L, Knight RA, Hodson ME. Independent genetic determinants of pancreatic and pulmonary status in cystic fibrosis. Lancet. 1990: 336:1081-5084.
15. Borgo G, Mastella G, Gasparini P, Zoranello A, Doro R, Pignatti PF. Pancreatic function and genetic deletion F508 in cystic fibrosis. J Med Genet. 1990; 27:665-669.
16. Campbell PW III, Phillips JA III, Krishnamani MR, Maness KJ, Hajinski TA. Cystic fibrosis: Relationship between clinical status and F508 deletion. J Pediatr. 1991; 118:239-241.
17. Johansen HK, Nir M, Hoiby N, Koch C, Schwartz M. Severity of cystic fibrosis in patients homozygous and heterozygous for ΔF508 mutation. Lancet. 1991; 337:631-634.
18. Hamosh A, King TM, Rosenstein BJ, Corey M, Levison H, Durie P, Tsui L-C, McIntosh I, Keston M, Brock DJH, Macek M Jr. Zemkova D, Krasnicanova H, Vavrova V, Milan M Sr, Golder N, Schwarz MJ, Super M, Watson EK, Williams C, Bush A, O'Mahoney SM, Humphries P, DeArce MA, Reis A, Burger J, Stuhrmann M, Schmidtke J, Wulbrand U, Dork T, Tummler B, Cutting GR. Cystic fibrosis patients bearing both the common missense mutation Gly → Asp at codon 551 and Δ508 mutation are clinically indistinguishable from Δ508 homozygotes except for decreased risk of meconium ileus. Am J Hum Genet. 1992; 51:245-250.
19. Osborn L, Santis G, Schwartz M, Klinger K, Dork D. McIntosh I, Schwartz M, Nunes V, Macek M Jr, Reiss J, Highsmith WE Jr, McMahon R, Novelli G, Malik N, Burger J, Anvret M, Wallace A. Williams C, Mathew C, Rozen R, Graham C, Gaparini P, Bal J, Cassiman JJ, Balassopoulou A, Davidow L, Raskin S, Kalaydijieva L, Kerem B, Richards S, Simon-Bouy B, Super M, Wulbrand U, Keston M, Estivill X, Vavrova V, Friedman KJ, Barton D, Dallapiccola B, Stuhrmann M, Beards F, Hill AJM, Pignatti PF, Cuppens H, Angelicheva D, Tummler B, Brock DJH, Casals T, Macek M, Schmidtke J, Magee AC, Bonizzato A, DeBoeck C. Kuffardjieva A, Hodson M, Knight RA. Incidence and expression of the N1303K mutation of the cystic fibrosis (CFTR) gene. Hum Genet. 1992; 89:653-658.
20. Kristidis P, Bozon D, Corey M, Markiewicz D, Rommens J, Tsui LC. Durie P. Genetic determinants of exocrine pancreatic function. Am J Hum Genet. 1992; 50:1178-1184.
21. Liechti-Gallati S, Bonsall I, Malik N, Schneider V, Kraemer LG, Ruedeberg A, Moser H, Kraemer R. Genotype-phenotype association in cystic fibrosis: Analysis of the ΔF508, R553X and 3905insT mutations. Pediatr Res. 1992; 32:175-178.
22. The Cystic Fibrosis Genotype-Phenotype Consortium. Correlation between genotype and phenotype in patients with cystic fibrosis. N Engl J Med. 1993; 329:1308-1313.
23. Angelicheva D, Boteva K, Jordanova A, Savov A, Kufardjieva A. Tolun A, Telatar M, Akarsubasi A, Koprubasi F, Aydogdu S, Demirkol M, Kurdoglu G, Constantinou-Deltas CD, Georgiou C, Dean H, Ivaschenko T. Baranov V. Kalaydjieval. Cystic fibrosis patients from the Black Sea region: The 1677delTA mutation. Hum Mutat. 1994; 3:353-357.
24. Moullier P, Jehanne M, Audrezet MP, Mercier B, Verlingue C, Quere I, Guillermit H, Raguenes O, Storni V, Rault F, Ferec C. Association of 1078delT cystic fibrosis mutation with severe disease. J Med Genet. 1994; 31:159-161.
25. Chillon M, Dork T, Casals J, Gimenez J, Fonknechten N. Will K, Ramos D, Nunes V, Estivill X. A novel donor splice site in intron 11 of the CFTR gene, creating a mutation 1811 + 1.6 kb A → G. produces a new exon: High frequency in Spanish cystic fibrosis chromosomes and association with severe phenotype. Am J Hum Genet. 1995; 56:623-629.
26. Estivill X, Ortigosa L, Perez-Frias J, Dapene J, Ferrer J, Pena J, Pena L, Llevadot R, Gimenez J, Nunes V, Cobos N, Vazquez C, Casals T. Clinical characteristics of 16 cystic fibrosis patients with the missense mutation R334W, pancreatic insufficiency mutation with variable age of onset and interfamilial clinical differences. Hum Genet. 1995; 95:331-336.
27. Stern RC, Doershuk C, Drumm ML. 3849 + 10 kb C →T mutation and disease severity in cystic fibrosis. Lancet. 1995; 346:274-276.
28. Gan KH, Veeze JH, van den Ouweland AMW, Halley DJJ, Scheffer H, van der Hout A, Overbeek SE, de Jongste JC, Bakker W, Heijerman GM. A cystic fibrosis mutation associated with mild lung disease. N Engl J Med. 1995; 333:95-99.
29. Varon R, Sturmann M, Macek M, Kufardjieva A, Angelicheva D, Magdorf K. Jordanoxa A, Savoy A. Wahn U, Macek M, Lalov V, Ianova T, Ellemunter H, Vavrova V, Ferak V, Kayserova H, Reis A, Kalaydjieva L. Pancreatic insufficiency and pulmonary disease in German and Slavic cystic fibrosis patients with the R347P mutation. Hum Mutat. 1995; 6:219-225.
30. Kerem E, Nissim M, Argaman Z, Yahav Y, Augarten A, Chiba O, Moran I, Kerem B. Extremely high variability of clinical presentation among patients carrying the missense mutation G85E. Pediatr Pulmonol. 1994; S10:212.
31. Chu CS, Trapnell BC, Curristin SM, Cutting GR, Crystal RG. Extensive posttranscriptional deletion of the coding sequences of part of nucleotide-binding fold 1 in respiratory epithelial mRNA transcripts of the cystic fibrosis transmembrane conductance regulator gene is not associated with the clinical manifestations of cystic fibrosis. J Clin Invest. 1992; 90:785-790.
32. Chu CS, Trapnell BC, Curristin S, Cutting GR, Crystal RG. Genetic basis of variable exon 9 skipping in cystic fibrosis transmembrane conductance regulator mRNA. Nature Genet. 1993; 3:151-156.
33. Osborne LR, Alton EWFW, Tsui LC. CFTR intron 9 poly-T tract length in men with congenital absence of the vas deferens. Pediatr Pulmonol. 1994; S10:214.
34. Chillon M, Casals T, Mercier B, Bassas L, Lissens W, Silber S, Romey M-C, Ruiz-Romero J, Verlingue C, Claustres M, Nunes V, Ferec C, Estivill X. Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N Engl J Med. 1995; 332:1475-1480.
35. Jarvi K, Zielenski J, Wilschanski M, Dune P, Buckspan M, Tullis E, Markievicz D, Tsui LC. Cystic fibrosis transmembrane conductance regulator and obstructive azoospermia. Lancet. 1995; 345:1578.
36. Kerem E, Harel-Rave N, Augarten A, Goshen R, Nissim-Rafinia M, Madjar I, Yahav Y, Bentur L, Rivlin J, Kerem B. Clinical presentation of patients carrying the ST thymidine tract in intron 8 - from healthy individuals to typical CF. Pediatr Pulmonol. 1995; S12:203.
37. Knowles MR, Gatzy J, Boucher R. Increased bioelectrical potential difference across respiratory epithelia in cystic fibrosis. N Engl J Med. 1981; 305:1489-1495.
38. Knowles MR, Paradiso AM, Boucher R. In vivo nasal potential difference: Techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis. Hum Gene Ther. 1995; 6:445-455.
39. Osborne LR, Lynch M, Middleton PG. Alton EWFW, Geddes DM, Pryor JR, Hodson ME, Santis GK. Nasal epithelial ion transport and genetic analysis of infertile men with congenital absence of the vas deferens. Hum Mol Genet. 1993; 2:1605-1609.
40. Veeze HJ, Halley DJJ, Bijman J, de Jongst JC, de Jongste HR, Sinaasappel M. Determinants of mild clinical symptoms in cystic fibrosis. Residual chloride secretion in rectal biopsies in relation to the genotype. J Clin Invest. 1994; 93:461-466.
41. Stern RC, Boat TF, Abramowsky CR, Matthews LW, Wood RE, Doershuk CF. Intermediate-range sweat chloride concentration and pseudoinonas bronchitis. A cystic fibrosis variant with preservation of exocrine pancreatic function. JAMA. 1978; 239:2676-2680.
42. Davis PB, Hubbard VS. Di Sant'Agnese PA. Low sweat electrolytes in a patient with cystic fibrosis. Am J Med. 1980; 69:643-646.
43. Romano L, Minicucci L, Schiaffino MC, Serravalle P. Diana MC, Romano C. Uncommon presenting manifestations of cystic fibrosis: A clinical alert. Padiatr Padol. 1995; 30:1-7.
44. Leoni G, Pitzalis S, Podda R, Zanda M, Silvetti M, Caocci L, Cao A, Rosatelli MC. A specific cystic fibrosis mutation (T338I) associated with the phenotype of isolated hypotonic dehydration J Pediatr. 1995; 127:281-283.
45. Holsclaw DS, Lobel B, Jockin H, Shwachman H. Genital abnormalities in male patients with cystic fibrosis. J Urol. 1971; 106:568-574.
46. Anguiano A, Oates RD, Amos JA, Dean M, Gerrard B, Stewart C, Maher TA, White MB, Milunsky A. Congenital bilateral absence of the vas deferens, a primary genital form of cystic fibrosis. JAMA. 1992; 267:1794-1797.
47. Osborne LR, Lynch M, Middleton PG, Alton EWFW, Geddes DM, Pryor JR, Hodson ME, Santis GK. Nasal epithelial ion transport and genetic analysis of infertile men with congenital absence of the vas deferens. Hum Mol Genet 1993; 2:1605-1609.
48. Culard JE Desgeorges M, Costa P, Laussel M, Razkatzara G, Navratil H, Demaille J, Claustres M. Analysis of the whole CFTR coding regions and splice junctions in azospermic men with congenital bilateral absence of epididymis or vas deferens. Hum Genet. 1994; 93:467-470.
49. Oates RD, Amos JA. The genetic basis of congenital absence of the vas deferens and cystic fibrosis. J. Androl. 1994; 15:1-8.
50. Mercier B, Verlingue C, Lissens W, Silber SJ, Novelli G, Bonduelle M, Audrezet MP, Ferec C. Is congenital bilateral absence of vas deferens a primary form of cystic fibrosis? Analyses of the CFTR gene in 67 patients. Am J Hum Genet. 1995; 56:272-277.
51. Casals T, Bassas L, Ruiz-Romero J, Chillon M, Gimenez J, Ramos MD, Tapia G, Narvaez H, Nunes V, Estivill X. Extensive analysis of 40 infertile patients with congenital absence of the vas deferens: In 50% of cases only one CFTR allele could be detected. Hum Genet. 1995; 95:205-211.
52. Rave-Harel N, Madgar I, Goshen R, Nissim-Rafina M, Ziadni A, Rahat A, Chiba O, Kalman YM, Brautbar C, Levison D, Augarten A, Kerem E, Kerem B. CFTR haplotype analysis reveals genetic heterogeneity in the etiology of congenital bilateral aplasia of the vas deferens. Am J Hum Genet. 1995; 56:1359-1366.
53. Tsui L-C. The spectrum of cystic fibrosis mutations. TIG. 1992; 8:392-398.
54. Sheppard DN, Carson MR, Ostedgaard LS, Denning GM, Welsh MJ. Expression of cystic fibrosis transmembrane conductance regulator in a model epithelium. Am J Physiol. 1994; 266:L405-L413.
55. Yang Y, Engelhardt JF, Wilson JM. Ultrastructural localization of variant forms of cystic fibrosis transmembrane conductance regulator in human bronchial epithelia of xenografts. Am J Respir Cell Mol Biol. 1994; 11:7-15.
56. Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell. 1993; 73:1251-1254.
57. Wilshanski M, Zielenski J, Markiewicz D, Tsui LC, Corey M, Levison H, Durie PR. Correlation of sweat chloride concentration with classes of the cystic fibrosis transmembrane conductance regulator gene mutations. J Pediatr. 1995; 127:705-710.
58. Kerem E, Kerem B. The relationship between genotype and phenotype in cystic fibrosis. Curr Opin Pulmonary Med. 1995; 1:450-456.
59. - channels by protein kinase A corrected by insertion of CFTR. Nature. 1992; 358:581-584.
60. + transport in cystic fibrosis respiratory epithelia. Abnormal basal rate and response to adenylate cyclase activation. J Clin Invest. 1986; 78:1245-1252.
61. Stutts JM, Canessa CM, Olsen JC, Hamrick M, Cohn JA, Rossier BC. Boucher RC. CFTR as a cAMP-dependent regulator of sodium channels. Science. 1995; 269:847-850.
62. Dork T, Wulbrand U, Richter T, Neumann T, Wolfes H, Wulf B, Maass E, Tummler B. Cystic fibrosis with three mutations in the cystic fibrosis transmembrane conductance regulator gene. Hum Genet. 1991; 87:441-446.
63. Kiesewetter S. Macek M Jr, Davis C, Currustin SM. Clin C-S, Graham C. Shrimpton AE. Cashman SM. Tsui L-C, Mickle J. Amos J, Highsmith WE, Shuber A, Witt DR, Crystal RG, Cutting GR. A mutation in CFTR produces different phenotypes depending on chromosomal background. Nature Genet. 1993; 5:274-278.
64. Shoshani T, Kerem E, Ben-Tur L, Tal A, Szeinberg A, Yahav Y, Augarten A, Kerem B. Association between pulmonary function and levels of aberrantly spliced mRNA transcribed in epithelial cells from the 3849 + 10 kb C→T alle 1. Pediatr Pulmonol. 1994; S10:213.
65. Kerem B, Rave-Harel N, Nissim-Rafina M, Goshen R, Madgar I, Augarten A, Kerem E. Variable levels of aberrantly spliced CFTR mRNA transcribed from the 5T allele: The cause for variable disease severity among individuals and between organs of the same individual. Am J Hum Genet. 1995; 857:1412.
66. Denning GM, Anderson MP, Amara JF, Marshall J, Smith AE, Welsh MJ. Processing of the mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature. 1992; 358:761-764.
67. Pignatti PF, Bombieri C, Mango C, Benetazzo M, Luisetti M. Increased incidence of cystic fibrosis gene mutations in adults with disseminated bronchiectasis. Hum Mol Genet. 1995; 4:635-639.
68. Dumur V, Lafitte JJ. Gervais R. Debaecker D, Kesteloot M, Lalau G, Roussel P. Abnormal distribution of cystic fibrosis ΔF508 allele in adults with chronic bronchial hypersecretion. Lancet. 1990; 335:1340.
69. Gervais R, Lafitte JJ, Dumur V, Kestelott M, Lalau G, Houdret N, Roussel P. Sweat chloride and ΔF508 mutation in chronic bronchitis or bronchiectasis. Lancet 1993; 342:997.
70. Simon-Bouy B, Stern M, Taillandier A, Mornet E, Boue A, Caubarrere I. Increased frequency of the ΔF508 mutation in patients with bronchiectasis. Pediatr Pulmonol. 1993; 59:237.
71. Miller PW, Macek M, Hamosh A, Walden S, Loury MC, Cutting GR. Identification of CETR mutations in adult patients with allergic bronchopulmonary aspergillosis and chronic pseudomonas bronchitis. Pediatr Pulmonol. 1993; 59:237.
72. Wiatrik BJ, Myer CM, Cotton RT. Cystic fibrosis presenting with sinus disease in children. Am J Dis Child. 1993; 147:258.
73. Burger J, Macek MJ, Stuhrman M, Reis A, Krawczak M. Schmidtke J. Genetic influences in the formation of nasal polyps. Lancet. 1991; 337:974.
74. Laroche D, Travert G. Abnormal frequency of ΔF508 mutation in neonatal transitory hypertrypsinemia. Lancet. 1991; 337:55.
75. Kerem B, Harel-Rave N, Nissim-Rafina M, Goshen R, Madjar I, Augarten A, Kerem E. Variable levels of aberrantly spliced CFTR mRNA transcribed from the 5T allele: The cause for variable disease severity among individuals and between organs of the same individuals. Am J Hum Genet. 1995; 357:1412.
76. Cystic fibrosis genotype-phenotype consortium. Variable phenotypes for nine CFTR mutations associated with pancreatic sufficiency in CF patients. Pediatr Pulmonol. 1996; 513:245.